Status: Recruiting
A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors
The goal of the phase 1 study is to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics activity of FP008 in subjects with advanced solid tumors.
Participants needed: 108
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Zhuhai Fapon Biopharma Co., Ltd.Updated: Aug 12, 2026Locations: 4
Eligibility criteria
Signed written ICF and be able to comply with the protocol. [+9]
Subjects who have received other IL-10 agents. [+8]